Bluejay Diagnostics raises $4.5 million in private placement

Bluejay Diagnostics Inc. (NASDAQ: BJDX) announced it has entered into definitive agreements for a private placement expected to raise $4.5 million in gross proceeds. The medical diagnostics company will sell 2.25 million shares of common stock and accompanying warrants at $2.00 per share.

The transaction includes Series F warrants to purchase up to 4.5 million additional shares of common stock. The warrants carry an exercise price of $1.75 per share and will be exercisable immediately upon issuance, expiring 5.5 years from the issuance date.

Rodman and Renshaw LLC serves as the exclusive placement agent for the offering, which is expected to close on or about October 10, 2025, subject to customary closing conditions.

The company stated it intends to use net proceeds to fund matters related to obtaining FDA approval, including clinical studies, as well as other research and development activities and general working capital needs.

The securities are being offered under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under federal securities laws. The company has agreed to file a resale registration statement covering the securities pursuant to a registration rights agreement with investors.

Bluejay Diagnostics develops near-patient diagnostic solutions for critical care, focusing on its Symphony System for sepsis triage and monitoring. The company's first product candidate is an IL-6 test for sepsis designed to provide results in approximately 20 minutes.

You May Also Be Interested In

• Osprey Acquisition Corp. III raises $300M in Nasdaq IPO
• Bending Spoons closes IPO, raises ~$954M on Nasdaq
• ITG, Inc. raises $323.4M in Nasdaq IPO at $16 per share